Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1998-09-08
2002-04-16
Raymond, Richard L. (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252010, C544S122000, C544S123000, C544S316000, C544S331000
Reexamination Certificate
active
06372741
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred.
BACKGROUND OF THE INVENTION
Chronic diseases are often accompanied by profound angiogenesis, which can contribute to or maintain an inflammatory and/or proliferative state, or which leads to tissue destruction through the invasive proliferation of blood vessels. EL-1&bgr; and TNF&agr; have been found to be potent inducers of angiogenesis in vivo and are commonly involved in the pathology of chronic inflammatory diseases (Folkman and Shing, J. Biol. Chem. 267:10931, 1992).
Angiogenesis is generally used to describe the development of new or replacement blood vessels, or neovascularisaflon. It is a necessary and physiologically normal process by which the vasculature is established in the embryo. Angiogenesis does not occur, in general, in the normal adult. Many diseases, however, are characterized by persistent and unregulated angiogenesis. For instance, in arthritis, new capillary blood vessels invade the joint and destroy cartilage (Colville-Nash and Scott, Ann. Rheum. Dis., 51, 919,1992). In diabetes, new vessels invade the vitreous and blood, and cause blindness (and may occur in many different eye diseases) (Brooks et al., Cell, 79, 1157, 1994). The process of atherosclerosis has been linked to angiogenesis (Kahlon et al., Can. J. Cardiol. 8, 60, 1992). Tumor growth and metasis have been found to be angiogenesis-dependent (Folkman, Cancer Biol, 3, 65, 1992; Denekamp, Br. J. Rad. 66, 181, 1993; Fidler and Ellis, Cell, 79, 185, 1994).
The recognition of the involvement of angiogenesis in major diseases has been accompanied by research to identify and develop inhibitors of angiogenesis. These inhibitors are generally classified in response to discrete targets in the angiogenesis cascade, such as activation of endothelial cells by an angiogenic signal; synthesis and release of degradative enzymes; endothelial cell migration; proliferation of endothelial cells; and formation of capillary tubules. Therefore, angiogenesis occurs in many stages and attempts are underway to discover and develop compounds that work to block angiogenesis at these various stages.
There are publications that teach that inhibitors of angiogenesis, working by diverse mechanisms, are beneficial in diseases such as cancer and metastasis (O'Reilly et al., Cell, 79, 315, 1994; Ingber et al., Nature, 348, 555, 1990), ocular diseases (Friedlander et al., Science, 270, 1500, 1995), arthritis (Peacock et al., J. Exp. Med. 175, 1135, 1992; Peacock et al., Cell. Immun. 160, 178, 1995) and hemangioma (Taraboletti et al., J. Natl. Cancer Inst. 87, 293, 1995).
A need still exists, however, to find suitable small molecule inhibitors which will block angiogenesis in a mammal for treatment of these diseases which have an angiogenic component. The current application teaches the novel finding that CSAID™ compounds, i.e. compounds that block cytokine production, can block angiogenesis by removing the early cytokine signals for angiogenesis.
SUMMARY OF THE INVENTION
The present invention is to the novel use of a cytokine inhibitor for the treatment of chronic inflammatory or proliferative or angiogenic diseases which are caused by excessive, inappropriate angiogenesis. The preferred compounds for use as cytokine inhibitors are those compounds of Formula (I) as noted herein. The preferred method of inhibition is the inhibition of the CSBP/p38/RK kinase pathway.
REFERENCES:
patent: 4808402 (1989-02-01), Leibovich et al.
patent: 5525604 (1996-06-01), Lee et al.
patent: 5525724 (1996-06-01), Hunds
patent: 5593992 (1997-01-01), Adams et al.
patent: 5658903 (1997-08-01), Adams et al.
patent: 6046208 (2000-04-01), Adams et al.
patent: WO93/14081 (1993-07-01), None
patent: WO93/14082 (1993-07-01), None
patent: WO 95/02591 (1995-01-01), None
patent: WO95/09841 (1995-04-01), None
patent: WO95/31451 (1995-11-01), None
Soni Chem. Abstract 97:216082., 1982.*
Ben Ezra et al., “In vivo angiogenetic activity of interleukins”,Archives of Ophthalmology, 108(4), pp. 573-576 (1990).
Jackson Jeffrey R.
Winkler James D.
Dinner Dara L.
Kinzig Charles M.
Rao Deepak R.
Raymond Richard L.
SmithKline Beecham Corporation
LandOfFree
Use of CSAID™ compounds as inhibitors of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of CSAID™ compounds as inhibitors of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of CSAID™ compounds as inhibitors of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2842689